Our expert talk about Generalized Cost-Effectiveness Analysis
On Monday, May 6 11:30am to 12:30pm, ISPOR attendees met Peter Kolchinsky, author of "The Great American Drug Deal”, founder of RA Capital and board member of No Patient Left Behind at the FIECON booth.
Peter is a staunch advocate for the Biotech Social Contract and Generalized Cost-Effectiveness Analysis (GCEA). Please check out the video to hear how the cost-effectiveness landscape is evolving in the US, through growing adoption of GCEA by investors and the industry.